

Bo Dupont

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1949596/publications.pdf>

Version: 2024-02-01

53
papers

6,713
citations

101543

36
h-index

182427

51
g-index

55
all docs

55
docs citations

55
times ranked

5208
citing authors

#	ARTICLE	IF	CITATIONS
1	Cell-Extrinsic MHC Class I Molecule Engagement Augments Human NK Cell Education Programmed by Cell-Intrinsic MHC Class I. <i>Immunity</i> , 2016, 45, 280-291.	14.3	58
2	Donor Activating KIR2DS1 in Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 2042-2042.	27.0	12
3	NK Cell Tolerance of Self-Specific Activating Receptor KIR2DS1 in Individuals with Cognate HLA-C2 Ligand. <i>Journal of Immunology</i> , 2013, 190, 4650-4660.	0.8	55
4	HLA-C-Dependent Prevention of Leukemia Relapse by Donor Activating KIR2DS1. <i>New England Journal of Medicine</i> , 2012, 367, 805-816.	27.0	398
5	Killer immunoglobulin-like receptor locus polymorphisms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 951-958.	3.0	18
6	Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. <i>Journal of Clinical Investigation</i> , 2012, 122, 3260-3270.	8.2	190
7	Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2010, 115, 3162-3165.	1.4	99
8	HLA Class I-Associated Immunodominance Affects CTL Responsiveness to an ESO Recombinant Protein Tumor Antigen Vaccine. <i>Clinical Cancer Research</i> , 2009, 15, 299-306.	7.0	18
9	Vaccination with Recombinant NY-ESO-1 Protein Elicits Immunodominant HLA-DR52b-restricted CD4+ T Cell Responses with a Conserved T Cell Receptor Repertoire. <i>Clinical Cancer Research</i> , 2009, 15, 4467-4474.	7.0	19
10	A Panel of Artificial APCs Expressing Prevalent HLA Alleles Permits Generation of Cytotoxic T Cells Specific for Both Dominant and Subdominant Viral Epitopes for Adoptive Therapy. <i>Journal of Immunology</i> , 2009, 183, 2837-2850.	0.8	33
11	KIR and HLA Genotypes Are Associated with Disease Progression and Survival following Autologous Hematopoietic Stem Cell Transplantation for High-Risk Neuroblastoma. <i>Clinical Cancer Research</i> , 2009, 15, 7330-7334.	7.0	117
12	The Lytic Potential of Human Liver NK Cells Is Restricted by Their Limited Expression of Inhibitory Killer Ig-Like Receptors. <i>Journal of Immunology</i> , 2009, 183, 1789-1796.	0.8	55
13	Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2008, 143, 641-653.	2.5	175
14	HLA alleles determine differences in human natural killer cell responsiveness and potency. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 3053-3058.	7.1	239
15	Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission. <i>Clinical Cancer Research</i> , 2008, 14, 2740-2748.	7.0	98
16	KIR2DS1-Positive NK Cells Mediate Alloresponse against the C2 HLA-KIR Ligand Group In Vitro. <i>Journal of Immunology</i> , 2007, 179, 854-868.	0.8	178
17	The Activating KIR2DS2 Gene Influences NK Alloreactivity and NK Repertoire.. <i>Blood</i> , 2007, 110, 313-313.	1.4	24
18	KIR Ligands and Prediction of Relapse after Unrelated Donor Hematopoietic Cell Transplantation for Hematologic Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 828-836.	2.0	201

#	ARTICLE	IF	CITATIONS
19	The Effect of KIR Ligand Incompatibility on the Outcome of Unrelated Donor Transplantation: A Report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 876-884.	2.0	241
20	The Activating KIR Genes 2DS1 and 2DS2 Regulate NK Alloreactivity In Vitro.. <i>Blood</i> , 2006, 108, 927-927.	1.4	0
21	Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. <i>Blood</i> , 2005, 105, 4878-4884.	1.4	437
22	Genetic interaction among three genomic regions creates distinct contributions to early- and late-onset type 1 diabetes mellitus. <i>Pediatric Diabetes</i> , 2005, 6, 213-220.	2.9	40
23	The Wiskott-Aldrich Syndrome Protein Regulates Nuclear Translocation of NFAT2 and NF- κ B (RelA) Independently of Its Role in Filamentous Actin Polymerization and Actin Cytoskeletal Rearrangement. <i>Journal of Immunology</i> , 2005, 174, 2602-2611.	0.8	57
24	Natural killer cell receptors: Regulating innate immune responses to hematologic malignancy. <i>Seminars in Hematology</i> , 2005, 42, 91-103.	3.4	32
25	Ligand Binding to Inhibitory Killer Cell Ig-Like Receptors Induce Colocalization with Src Homology Domain 2-Containing Protein Tyrosine Phosphatase 1 and Interruption of Ongoing Activation Signals. <i>Journal of Immunology</i> , 2004, 173, 1571-1578.	0.8	36
26	Vaccine-Induced CD4+ T Cell Responses to MAGE-3 Protein in Lung Cancer Patients. <i>Journal of Immunology</i> , 2004, 172, 3289-3296.	0.8	176
27	Inhibitory killer Ig-like receptor genes and human leukocyte antigen class I ligands in haematopoietic stem cell transplantation. <i>Current Opinion in Immunology</i> , 2004, 16, 634-643.	5.5	54
28	The yin-yang in immunity. <i>Blood</i> , 2004, 104, 3002-3003.	1.4	0
29	The Effect of Killer Immunoglobulin-Like Receptor (KIR) Ligand Incompatibility on Outcome of Unrelated Donor Bone Marrow Transplantation (UDT).. <i>Blood</i> , 2004, 104, 434-434.	1.4	7
30	Killer-cell Immunoglobulin-like Receptor (KIR) Nomenclature Report, 2002. <i>Human Immunology</i> , 2003, 64, 648-654.	2.4	135
31	Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 8862-8867.	7.1	179
32	Evasion from NK Cell Immunity by MHC Class I Chain-Related Molecules Expressing Colon Adenocarcinoma. <i>Journal of Immunology</i> , 2003, 171, 6891-6899.	0.8	295
33	Cutting Edge: Differential Segregation of the Src Homology 2-Containing Protein Tyrosine Phosphatase-1 Within the Early NK Cell Immune Synapse Distinguishes Noncytolytic from Cytolytic Interactions. <i>Journal of Immunology</i> , 2002, 168, 3150-3154.	0.8	76
34	Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon- γ production and growth of cytotoxic precursors. <i>Blood</i> , 2002, 99, 1730-1740.	1.4	66
35	Killer Ig-Like Receptor Haplotype Analysis by Gene Content: Evidence for Genomic Diversity with a Minimum of Six Basic Framework Haplotypes, Each with Multiple Subsets. <i>Journal of Immunology</i> , 2002, 169, 5118-5129.	0.8	361
36	Nomenclature for factors of the HLA system, 2002. <i>Tissue Antigens</i> , 2002, 60, 407-464.	1.0	179

#	ARTICLE	IF	CITATIONS
37	Introduction: current concepts in immunity to human cancer and therapeutic antitumor vaccines. <i>Immunological Reviews</i> , 2002, 188, 5-8.	6.0	12
38	Visualization of cognate interactions in immune responses. <i>Immunological Reviews</i> , 2002, 189, 5-7.	6.0	0
39	Visualization of signaling pathways and cortical cytoskeleton in cytolytic and noncytolytic natural killer cell immune synapses. <i>Immunological Reviews</i> , 2002, 189, 161-178.	6.0	91
40	The killer cell immunoglobulin-like receptor (KIR) genomic region: gene order, haplotypes and allelic polymorphism. <i>Immunological Reviews</i> , 2002, 190, 40-52.	6.0	406
41	Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program Experience. <i>Blood</i> , 2001, 98, 2922-2929.	1.4	138
42	Nomenclature for factors of the HLA system, 2000. <i>International Journal of Immunogenetics</i> , 2001, 28, 377-424.	1.2	18
43	Spatial Organization of Signal Transduction Molecules in the NK Cell Immune Synapses During MHC Class I-Regulated Noncytolytic and Cytolytic Interactions. <i>Journal of Immunology</i> , 2001, 167, 4358-4367.	0.8	161
44	Nomenclature for factors of the HLA system, 1996. <i>Tissue Antigens</i> , 1997, 49, 297-321.	1.0	262
45	Immunology of hematopoietic stem cell transplantation: a brief review of its history. <i>Immunological Reviews</i> , 1997, 157, 5-12.	6.0	19
46	Polymorphism and domain variability of human killer cell inhibitory receptors. <i>Immunological Reviews</i> , 1997, 155, 183-196.	6.0	61
47	Nomenclature for factors of the HLA system, 1994. <i>Tissue Antigens</i> , 1994, 44, 1-18.	1.0	252
48	Description of the Reference Panel of B-Lymphoblastoid Cell Lines for Factors of the HLA System: The B-Cell Line Panel Designed for the Tenth International Histocompatibility Workshop. , 1989, , 11-19.		107
49	Adrenal 21-Hydroxylase Cytochrome P-450 Genes within the MHC Class III Region. <i>Immunological Reviews</i> , 1985, 87, 123-150.	6.0	34
50	Reconstitution in Severe Combined Immunodeficiency by Transplantation of Marrow from an Unrelated Donor. <i>New England Journal of Medicine</i> , 1977, 297, 1311-1318.	27.0	170
51	Comparison of multiple in vivo and in vitro parameters in untreated patients with Hodgkin's disease. <i>Cancer</i> , 1976, 38, 1807-1815.	4.1	70
52	Mixed Lymphocyte Culture Technique: Standardization of a Test System with 10^5 Responding and 10^5 Stimulating Lymphocytes per 1 ml. <i>Tissue Antigens</i> , 1974, 4, 495-506.	1.0	24
53	HISTOCOMPATIBILITY DETERMINANTS IN MULTIPLE SCLEROSIS, WITH SPECIAL REFERENCE TO CLINICAL COURSE. <i>Lancet</i> , The, 1973, 302, 1221-1225.	13.7	426